Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

Allogeneic hematopoietic cell transplantation (HCT) has curative potential for several hematologic malignancies. There has been a considerable increase in the number of partially matched (haploidentical) transplantations performed worldwide [1]. Traditionally, haploidentical HCT has been associated with substantial bidirectional alloreactivity, which often results in graft failure or severe graft-versus-host disease (GVHD). However, the use of post-transplantation cyclophosphamide (PTCy) in the haploidentical HCT platform has resulted in improved GVHD rates and overall outcomes comparable to those in fully matched donor HCT; thus, the PTCy platform is being increasingly applied in the matched donor setting [2].

Source: Biology of Blood and Marrow Transplantation - September 26, 2021 Category: Hematology Authors: Anurag Singh, Christopher E. Dandoy, Min Chen, Soyoung Kim, Carolyn M. Mulroney, Mohamed A. Kharfan-Dabaja, Siddhartha Ganguly, Richard T. Maziarz, Christopher G. Kanakry, Jennifer A. Kanakry, Sagar S. Patel, Joshua A. Hill, Satiro De Oliveir, Randy Tapli Source Type: research